- Home
- RVT vs AGIO Comparison
RVT vs AGIO Comparison
Compare RVT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVT | AGIO |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | RVT | AGIO |
|---|---|---|
| Price | $16.71 | $29.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.88 |
| AVG Volume (30 Days) | 250.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $227.92 |
| Revenue Next Year | N/A | $96.10 |
| P/E Ratio | $5.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.97 | $22.24 |
| 52 Week High | $19.12 | $46.00 |
Technical Indicators
Market Signals| Indicator | RVT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 37.69 |
| Support Level | $15.84 | $26.41 |
| Resistance Level | $18.63 | $29.78 |
| Average True Range (ATR) | 0.28 | 1.79 |
| MACD | 0.04 | -0.81 |
| Stochastic Oscillator | 27.96 | 14.74 |
Price Performance
Historical ComparisonAbout RVT Royce Value Trust Inc.
Royce Small-Cap Trust Inc is a diversified closed-end investment company that invests in equity securities of small-cap companies. The company portfolio includes sectors such as Industrials, Financials, Information Technology, Health Care, and Consumer Discretionary.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.